SCHEDULE: Stonepine Capital Discloses 9.9% Stake in Cellectar

Stonepine Capital Management has reported a 9.9% beneficial ownership stake in Cellectar Biosciences following recent equity and warrant issuances.

Summary

• Stonepine Capital Management, LLC, along with its affiliates and Jon M. Plexico, reported a 9.9% beneficial ownership stake in Cellectar Biosciences, Inc.
• The holdings consist of 196,930 shares of common stock and prefunded warrants to acquire 912,075 shares.
• The warrants are subject to a 9.99% beneficial ownership limitation.
• The ownership percentage is based on 7,975,069 total shares outstanding as of May 4, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming institutional support following a recent capital raise.

Positives

• Institutional investor maintains a significant 9.9% position, signaling confidence in the company's long-term prospects.

Negatives

• The position includes a large portion of warrants (912,075 shares) rather than direct common stock, which may create future dilution pressure.

Risks

• The 9.99% beneficial ownership limitation on warrants restricts the ability of the reporting person to exercise their full position without further regulatory filings or market adjustments.
• Potential for future dilution of existing shareholders upon the exercise of the prefunded warrants.

Future Outlook

The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing reflects standard institutional activity following a capital raise in the biotechnology sector, where investors often utilize prefunded warrants to manage ownership thresholds and regulatory reporting requirements.

Comparison to Industry Standards

• The 9.9% ownership stake is a common threshold for institutional investors in small-cap biotech to maintain significant influence without triggering more stringent 13D reporting requirements.
• The use of prefunded warrants is a standard mechanism in biotech financing to provide immediate capital while deferring full equity conversion.

Stakeholder Impact

• Shareholders should note the potential for future dilution if the 912,075 warrants are exercised.
• The presence of a 9.9% institutional holder provides a degree of stability to the share register.

Next Steps

• Potential future exercise of prefunded warrants by Stonepine Capital.
• Ongoing monitoring of ownership levels relative to the 9.99% limitation.

Key Dates

Keywords

Cellectar Biosciences, Stonepine Capital, Schedule 13G, Beneficial Ownership, Biotech Investment, Prefunded Warrants